Cancer: Still a contraindication for allergen immunotherapy? Specific immunotherapy and cancer

被引：3
|
作者：
El-Qutob, David [1 ]
Letran, Antonio [2 ]
Matheu, Victor [3 ]
Fernandez-Caldas, Enrique [4 ,5 ]
机构：
[1] Univ Hosp La Plana, Allergy Unit, Vila Real, Spain
[2] Hosp HLA Jerez Puerta Sur, Allergy Unit, Cadiz, Spain
[3] Univ Hosp Canarias, Serv Allergol, Tenerife, Spain
[4] Inmunotek SL, Madrid, Spain
[5] Univ S Florida, Coll Med, Tampa, FL 33620 USA
来源：
WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 10期
关键词：
Cancer; Neoplasm; Specific immunotherapy; Allergen; Contraindication; GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; MALIGNANCY; EXPERIENCE; MECHANISMS; INDUCTION; DISEASES; IL-10; IGG4; IGE;
D O I：
10.1016/j.waojou.2021.100597
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Allergen immunotherapy (AIT) is currently more than 100 years old. It is considered an evidencebased efficacious immune therapeutical treatment. It is at this time the only causative treatment for allergic respiratory and venom allergic diseases. Though clinical indications for AIT are well established, clinical contraindications to AIT differ among several guidelines. Regarding malignant neoplasia, traditionally, it has been considered as a relative or absolute contraindication with the concern that AIT might stimulate tumour growth even though pathogenic impact of AIT in cancer is not well understood. Furthermore, this contraindication is often based on observational case series, or case reports, with little real evidence-based data. Therefore, should cancer still be contemplated as an absolute contraindication for AIT? Keywords: Cancer, Neoplasm, Specific immunotherapy, Allergen, Contraindication
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Persistence and evolution of allergen-specific IgE repertoires during subcutaneous specific immunotherapy
    Levin, Mattias
    King, Jasmine J.
    Glanville, Jacob
    Jackson, Katherine J. L.
    Looney, Timothy J.
    Hoh, Ramona A.
    Mari, Adriano
    Andersson, Morgan
    Greiff, Lennart
    Fire, Andrew Z.
    Boyd, Scott D.
    Ohlin, Mats
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (05) : 1535 - 1544
  • [32] Allergen Specific Immunotherapy in Canine Atopic Dermatitis: an Update
    Fischer, Nina M.
    Mueller, Ralf S.
    CURRENT DERMATOLOGY REPORTS, 2019, 8 (04) : 297 - 302
  • [33] Allergen Immunotherapy and Tolerance
    Matsuoka, Tomokazu
    Shamji, Mohamed H.
    Durham, Stephen R.
    ALLERGOLOGY INTERNATIONAL, 2013, 62 (04) : 403 - 413
  • [34] The Molecular Allergen Recognition Profile in China as Basis for Allergen-Specific Immunotherapy
    D'souza, Nishelle
    Weber, Milena
    Sarzsinszky, Eszter
    Vrtala, Susanne
    Curin, Mirela
    Schaar, Mirjam
    Garib, Victoria
    Focke-Tejkl, Margarete
    Li, Yanqiu
    Jones, Richard
    Chen, Hao
    Valenta, Rudolf
    Sun, Baoqing
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] Allergen-related approaches to immunotherapy
    Rolland, Jennifer M.
    Gardner, Leanne M.
    O'Hehir, Robyn E.
    PHARMACOLOGY & THERAPEUTICS, 2009, 121 (03) : 273 - 284
  • [36] Role of allergen-specific T-follicular helper cells in immunotherapy
    Yao, Yin
    Wang, Zhi-Chao
    Yu, Di
    Liu, Zheng
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 18 (06) : 495 - 501
  • [37] Microbial Adjuncts for Food Allergen Immunotherapy
    Ho, Hsi-en
    Bunyavanich, Supinda
    CURRENT ALLERGY AND ASTHMA REPORTS, 2019, 19 (05)
  • [38] Molecular profile clustering of allergen-specific IgE responses and potential implications for specific immunotherapy
    Hofmaier, S.
    Hakimeh, D.
    Hatzler, L.
    Matricardi, P. M.
    ALLERGOLOGIE, 2013, 36 (09) : 420 - 426
  • [39] Allergen-specific immunotherapy. Hyposensitization
    Wedi, B
    Kapp, A
    HAUTARZT, 2004, 55 (04): : 399 - 407
  • [40] Role of immunmodulators in allergen-specific immunotherapy
    Kopp, M. V.
    ALLERGY, 2011, 66 (06) : 792 - 797
12345